

# La Physique Médicale demain: Perspectives en Radiothérapie

A.Mazal, P.Francois, N.Fournier-Bidoz, R.Belshi

M. Dutreix, S. Heinrich, C. Wessels, A.Fourquet

Service de Physique Médicale  
Dept de Radiothérapie Oncologique  
Institut Curie, France

Journée Internationale de la Physique Médicale  
Institut Curie, 7 Novembre 2013

Remerciements: J-C.Rosenwald,  
P.Lambin (Maastro), D.Verellen,  
T.Lomax, G.Olivera, D.Galmarini


.....

France-Hadron, Areva, Cancéropôle




## EDITOR'S PICKS


### Imagerie




Dose equations for tube current modulation in CT scanning and the interpretation of the associated  $CTDI_{vol}$




Oblique reconstructions in tomosynthesis. I. Linear systems theory



Oblique reconstructions in tomosynthesis. II. Super-resolution



Dimensionality and noise in energy selective x-ray imaging



Evaluating IMRT and VMAT dose accuracy: Practical examples of failure to detect systematic errors when applying a commonly used metric and action levels

## MOST READ THIS MONTH

Increasing dependence on industry-funded research creates higher risk of biased reporting in medical physics

Vision 20/20: Single photon counting x-ray detectors in medical imaging

The more important heavy charged particle radiotherapy of the future is more likely to be with heavy ions rather than protons

## MOST CITED THIS MONTH

Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43

### Dosimetry

BEAM: A Monte Carlo code to simulate radiotherapy treatment units

### Evaluation de la dose

A technique for the quantitative evaluation of dose distributions



Most read

Most cited

Latest articles

Featured articles

Review articles

In the last 30 days

1. Optical properties of biological tissue

“Autres”

2. CT : Modelling Iterative reconstruction

3. MRI analysis for brain tumor studies

4. MRI Tracer kinetic modelling

5. X-ray phase-contrast imaging

“Imagerie”

6. Brachytherapy : Monte Carlo calculated doses for permanent implant in lung

7. Out-of-field dose in photon craniospinal irradiation

8. Dosimetry: when  $^{60}\text{Co}$  is the reference quality for charged-particle and photon beams

“Dosimétrie”

9. Automatic 3D ultrasound calibration in IGRT

10. Automated segmentation of pulmonary structures in CT

Outils  
“automatiques”

Comme  
“Evaluation”  
en Med Phys...

# **La Physique Médicale demain:** **Perspectives en Radiothérapie Externe**

## **Menu du jour :**

- 1) Physique et technologie :  
    vers la radiothérapie Adaptative**
- 2) Besoin d'ouverture en R&D :  
    vers la Biologie**
- 3) Divers, discussion et conclusions**




# Physique et technologie : Les systèmes proposés actuellement en RT externe



RapidArc ou équivalentes ([wphospitals.org](http://wphospitals.org))



[www.cyberknife.com](http://www.cyberknife.com)



Tomothérapie




Vero




ViewRay (MRI+3Co-60 w/MLC)


# La multiplicité d'incidences // Le rôle de l'Energie



1 Beam




5 Beams




11 Beams


17 Beams



25 Beams



51 Beams




(from Tomotherapy)







Electrons

Protons/Ions

Photons



J-C.Rosenwald









# L'évolution technologique en hadronthérapie




Machines plus compactes




Bras isocentriques




Robotique de positionnement



Cryogénie



Accélérateur a paroi dielectrique



Accélération Laser

# Hadrontherapy : Physical selectivity and/or Radiobiological effects

- \* pions
- \* fast
- & slow neutrons



*(Past)*

- \* protons

*(Present)*

- \* light and heavy ions

*(Future ?)*




Raju & Koehler, 1980

# Radiation Biology:


## Dose distribution in nanometer scale

M. Kraemer






# Au top de la sygmoïde de contrôle local ??



Ex sarcomes de la base du crâne

Darmstadt & Heidelberg

# Dosimetric comparisons: systems available at Institut Curie



LinacVarian 2100CSE





Tomotherapy HD





IBA protontherapy system

# IMRT fixed VS RapidArc










# Dose to femoral head [Gy] : Ratios vs Brachytherapy

Point dose to femoral head		
[Gy]	D femur	Ratio
Brachy	1.5	1
RapidArc	10	7
Tomo	15	10
Prot4	17	11
Prot5	17	11
ProtPatch	20	13
IMRT	30	20
Prot2	35	23
Conformal	50	33




For 1.5 Gy (max) given by Brachy to the femoral heads, all the others techniques deliver 10 to 50 Gy, so a ratio of 7 to 30 times higher

# L'évolution des outils logistiques :



Imagerie multimodalité :

Correlation d'images, Outils de contourage



En cours d'introduction:  
"Fast  
Knowledge based  
Planning"

Systèmes de planification : IMRT, 4D





# IGRT : Image Guided Radiation Therapy




**(The Tree of Imaging in Radiation Therapy)**


**Creteil, EPU G.Marinello**

*Lapacho (Tecoma curialis)*





# 7. Dose delivered per image







## Physique médicale demain: Perspectives en Radiothérapie




*Dirk Verellen. Brussels. Belgium*

- *Poor quality RT will produce poor quality clinical outcome*



- We need to “see” the tumor, the micro-environment and to “*see our scalpel*”



- We *need to redesign the QA process*, and to perform a *process oriented risk analysis*.





## Physique médicale demain: Perspectives en Radiothérapie



**Dirk Verellen. Brussels. Belgium  
(2/2)**

- Our priority is **NOT the development of new beams and new fancy machines**
- We need accurate reports of the **actual delivered dose** at each fraction ...
- We need good **data mining tools** from different hospitals
- Then we might start to understand the **radiobiology of the tumor and healthy tissues**, ...



# Ideas for Medical Physics in the future


## Tony Lomax, Switzerland

- Automated, risk minimised and time efficient QA
- Daily Adapted Treatments (real-time)  
In-vivo dose/range verifications/reconstructions
- Biological assessment based on accurate treatment dose distributions/reconstructions
- From Macro to micro : cellular level




# Adaptive : the workflow


Planning Imaging



Treatment Planning




Electronic Prescription




G. Olivera D.Galmarini  
USA

# The workflow


Planning Imaging



Treatment Planning




Electronic Prescription



2D – 3D In room Imaging



# The workflow

Planning Imaging




Electronic Prescription

Treatment Planning






# The workflow







# The workflow






Claas Wessels,  
PhD student, I. Curie

Incertitudes  
en niles techniques:  
rotationnelles  
et protons






fract	date.time	similarity	outputM	gamma	Com
1	<a href="#">20130826</a>	Yellow	Yellow	Green	
2	<a href="#">20130827</a>	Green	Yellow	Green	
3	<a href="#">20130828</a>	Yellow	Green	Yellow	
4	<a href="#">20130829</a>	Green	Green	Green	
5	<a href="#">20130830</a>	Green	Yellow	Yellow	
6	<a href="#">20130902</a>	Green	Green	Green	
7	<a href="#">20130903</a>	Yellow	Red	Red	Intern
8	<a href="#">20130904</a>	Green	Green	Green	
9	<a href="#">20130905</a>	Green	Green	Green	
10	<a href="#">20130906</a>	Yellow	Green	Green	
11	<a href="#">20130909</a>	Green	Green	Green	
12	<a href="#">20130910</a>	Green	Green	Green	
13	<a href="#">20130911</a>	Green	Green	Green	
14	<a href="#">20130912</a>	Green	Green	Green	
15	<a href="#">20130913</a>	Yellow	Green	Green	
16	<a href="#">20130916</a>	Green	Green	Green	
17	<a href="#">20130917</a>	Yellow	Green	Green	
18	<a href="#">20130918</a>	Green	Green	Green	
19	<a href="#">20130919</a>	Green	Green	Green	
20	<a href="#">20130920</a>	Green	Yellow	Green	
21	<a href="#">20130923</a>	Green	Yellow	Red	Intern
22	<a href="#">20130924</a>	Green	Red	Green	
23	<a href="#">20130925</a>	Green	Green	Green	
24	<a href="#">20130926</a>	Yellow	Green	Green	
25	<a href="#">20130927</a>	Green	Green	Green	
26	<a href="#">20130930</a>	Green	Green	Yellow	
27	<a href="#">20131001</a>	Green	Green	Green	
28	<a href="#">20131002</a>	Yellow	Green	Yellow	
29	<a href="#">20131003</a>	Yellow	Green	Green	
30	<a href="#">20131004</a>	Green	Green	Green	
31	<a href="#">20131007</a>	Yellow	Green	Green	
32	<a href="#">20131008</a>	Yellow	Green	Green	
33	<a href="#">20131009</a>	Yellow	Green	Yellow	





# Positron Emission Tomography from patient activation with the beam




W. Enhardt et al



## Prompt Gamma



F. Roellinghoff.  
 PhD, IBA.



## Knife-edge slit camera





# One idea/vision on physics in radiation therapy tomorrow?

---

**Thomas Bortfeld, Boston, USA**

- 1. We have almost plateaued out in the dose conformation problem (100 years)**
- 2. Optimization of dose delivery over time (hypo-fractionation,...), biological targeting, combined modalities (chemo-RT),....**
- 3. Cost-effectiveness in healthcare (cheaper treatments)**

**→ research in Medical Physics!**

# LUNG


**Proton dose escalation still spares more normal tissues**

**Proton 87.5 GY vs photon 60 GY in stage I**

**Proton 74 GY vs photon 60 Gy in stage III**

(Chang et al: Int J Rad Onc Bio Phys 65:1087-96, 2006)

## Stage III










# PET Guided Radiotherapy

Philippe Lambin,  
Maastrou, Belgium




Van Elmpt et al



Ling et al

Drug Uptake  
89Zirconium – Cetuximab

« Cold spot »:  
Less Drug Uptake  
(GTV<sub>LDU</sub>)



Aerts et al




# R&D Early cell response to split-dose irradiation

“W-Effect”

Ponette et al. (2000) *Int J Radiat Biol* 76: 1233-43 - Fernet et al. *Int J Radiat Biol* 76: 1621-29



Vincent Favaudon



Effet dans le temps...



# Novel RT techniques based on "different" dose delivery methods


## Combination

Very small field sizes ( $< 1\text{mm}^2$ )





+

spatial fractionation of the dose

### Dose-volume effects




Zeman et al., Science (1959)



# X-rays minibeam radiation therapy

## Minibeam Radiation Therapy (MBRT)




Extremely high resistance ( $> 100$  Gy in one fraction) of healthy rat brain & increase of lifespan of glioma bearing rats

*Prezado et al., J. Synchr. Radiat. 2012*

# Proton-minibeam radiation therapy



+



Proof of concept: promising dose distributions (*Prezado et al., Med. Phys. 2013*)

Biological experiments warranted

**Perspectives:** technical implementation at CPO (Orsay), development of dosimetry tools & radiobiological studies






# Radiosensitization by gold nanoparticles: effective at megavoltage energies and potential role of oxidative stress


Karl T. Butterworth, Stephen J. McMahon, Laura E. Taggart, Kevin M. Prise

Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, UK

Corresponding to: Karl T. Butterworth, Ph.D. Centre for Cancer Research & Cell Biology, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland, UK. Email: k.butterworth@qub.ac.uk.



**Figure 1** Comparison of the photon mass energy absorption coefficients for gold and soft tissue. The ratio of the mass energy absorption coefficients is shown as a function of photon energy. Data taken from Hubbell and Seltzer (1)



**Figure 3** Comparison of predicted and observed experimental dose enhancement for gold nanoparticle studies conducted using kilovoltage ( $\nabla$ ) and megavoltage ( $\blacktriangle$ ) energy sources. "Increase in physical dose" here refers to the ratio of the additional dose deposited by X-rays in the system due to the addition of GNPs to that which would be deposited in the absence of gold. The dashed line shows the trend which would be followed if the sensitizer enhancement ratio directly followed predicted increases in physical dose



Gold nanoparticles  
Butterworth et al  
Translat Cancer Res, 2013

In vitro

In vivo


**Table 1** Summary of experimental parameters for investigations demonstrating the radiosensitizing properties of GNPs *in vitro*

Author	Size (nm)	Concentration	Surface coating	Cell model	Source energy	Observed SE <sup>-</sup>
Butterworth <i>et al.</i> (30)	1.9	2.4 μM	Thiol	DU-145	160 kVp	<1
		0.24 μM		MDA231MB		<1.67
				AG0-1522		<1.97
				Astro		<1.04
				L132		<1
				T98G		<1.91
				MCF-7 PC-3		<1.41 <1.07
Chang <i>et al.</i> (31)	13	11 μM	Citrate	B16F10	6 MV e <sup>-</sup>	1
Chien <i>et al.</i> (32)	20	<2 mM	Citrate	CT-26	6 MV	1.19
Chithrani <i>et al.</i> (33)	14	1 μM	Citrate	HeLa	220 kVp	1.17-1.6
	74				6 MV e <sup>-</sup>	
	50				662 keV	
Coulter <i>et al.</i> (34)	1.9	12 μM	Thiol	DU-145 MDA-231MB L132	160 kVp	<1.8
Geng <i>et al.</i> (35)	14	5 μM	Glu*	SK-OV-3	90 kVp	1.3
					6 MV	1.2
Jain <i>et al.</i> (36)	1.9	12 μM	Thiol	DU-145	160 kVp	<1.41
				MDA-231MB	6 MV	<1.29
				L132	15 MV	1.16
					6 MeV e <sup>-</sup> 16 MeV e <sup>-</sup>	<1.12 1.35
Kong <i>et al.</i> (37)	10.8	15 nM	Glu* AET <sup>^</sup>	MCF-7 MCF-10A	200 kVp 662 keV	1.3 1.6
					1.2 MV	
Lui <i>et al.</i> (38)	6.1	>1 mM	PEG <sup>∇</sup>	CT-26 EMT-6	6 keV 160 kVp	2 1.1
					6 MV	1
Rahman <i>et al.</i> (39)	1.9	<1 mM	Thiol	BAEC	80 kV	20
					150 kV	1.4
					6 MV e <sup>-</sup>	2.9
					12 MV e <sup>-</sup>	3.7
Roa <i>et al.</i> (40)	10.8	15 nM	Glu*	DU-145	662 keV	>1.5
Zhang <i>et al.</i> (41)	30	15 nM	Glu*	DU-145	200 kVp	>1.3

\*thiogluucose; ^cysteamine; ∇polyethyleneglycol; <sup>-</sup>Sensitizer enhancement defined as the level of radiosensitization observed when

**Table 2** Summary of experimental parameters for investigations demonstrating the radiosensitizing properties of *in vivo*

Author	Size (nm)	Surface coating	Dose (g/kg <sup>-1</sup> )	Tumour conc (mg/g <sup>-1</sup> )	Cell model	Source energy	Outcome
Chang <i>et al.</i> (31)	13	Citrate	0-0.036	74	B16F10	6 MeV e <sup>-</sup>	MS
Hainfeld <i>et al.</i> (42)	1.9	Thiol	0-2.7	7	EMT-6	250 kVp	1 year OS
Hainfeld <i>et al.</i> (43)	1.9	Thiol	0-2.7	7	SCCVII	68 keV	OS
						157 keV	
Hainfeld <i>et al.</i> (44)	11	Thiol	0-4	1.5	Tu-2449	100 kVp	1 year OS
Hebert <i>et al.</i> (45)	5	DTDTPA-Gd	0-0.675	0.1	MCF7-L1	150 kVp	MS



Erika PORCEL

Institut des Sciences Moléculaires d'Orsay


Soutenance de thèse

Direction : S. LACOMBE




Comprendre le monde, construire l'avenir®

# Utilisation des Nanoparticules pour améliorer les performances de la Hadronthérapie




Gadolinium



Platine



Remita et al






Mowat et al





# Multidisciplinarité : besoin d'un langage commun

« Hadrontherapy » for a physicist?



## Measurements



$$(dE/dx) = 4 \pi z_{\text{eff}}^2 e^4 N_A Z/A m_e v^2 \{ \ln (2mv^2 / I (1-\beta^2)) - \beta^2 - \Sigma(C_i/Z) \}$$

$$\theta_0 = 14.1 z / p v \{ \text{sqrt} ( L / L_R ) ( 1 + \log(L / L_R ) / 9 ) \}$$



# « Hadrontherapy » for the physician

## 2. 筑波大学の陽子線治療成績

筑波大学の陽子線治療は、1983年以来色々な部位を対象に行われていますが、なかでも日本人に多い深部臓器がんに主体を置いているという特徴があります。表5に治療部位と治療成績を揚げました。これまでの経験で、皮膚、頭頸部、肺、食道、肝臓、子宮、膀胱、前立腺などで満足すべき結果が得られています。

第6図から第14図までは、実際に陽子線で治療した患者さんの写真です。




表5 筑波大学の陽子線治療結果

部位	患者数	局所治療率 推定(%)	3年 後遺症 生存率	
皮膚	8	7 (87.5)	87.5	0
脳脊髄腫など	13	3 (23.1)	18.5	3
頭頸部	15	11 (73.3)	81.5	0
肺	19	14 (73.7)	54.1	1
食道	23	18 (78.3)	51.6	3
肝臓	30	26 (86.7)	25.5*	0
胃	5	3 (60.0)	61.0	0
腎臓	5	2 (40.0)	60.0	0
子宮	24	21 (87.5)	72.7	3
膀胱	12	8 (66.7)	62.5	2
前立腺	7	7 (100.0)	68.6	0
小児腫瘍	4	4 (100.0)	75.0	0
その他	4	3 (75.0)	100.0	1
合計	178	135 (75.8)		13(7.1%)

\*肝機能良好例の3年生存率75.0%

# « La physique médicale demain: perspectives en radiothérapie »

## Vue de la Biologie




Marie Dutreix

1950


Une dosimétrie  
Multi-échelle



2D



3D



4D

Les techniques et les instruments ont progressé plus vite que notre connaissance des effets que ces rayons induisent sur le vivant

Radiothérapie conformationnelle  
Radiation avec modulation d'intensité (IMRT) et arc thérapie volumétrique (VMAT)

2013

**TISSU SAIN & TISSU TUMORAL , QUELLE DOSE?**

?  
**Plusieurs challenges liés aux nouveaux faisceaux**

- les micro- et mini-faisceaux
- les ultrahauts débits de dose (irradiations pulsées)
- l'hadronthérapie
- les plasmas...

**Plusieurs challenges liés aux combinaisons**

- nanoparticules à effet amplificateur des rayons
- thérapies ciblées (inhibiteurs de l'angiogénèse, de la réparation, du cycle...)

DOSE relative?

DOSE cumulée?

DOSE biologique?

DOSE apparente?

**L'intégration de la Physique et de la Biologie: une révolution à venir!**

# EXPERIMENTAL RADIOTHERAPY FACILITY



institutCurie  
Ensemble, prenons le cancer de vitesse.

## Radiations sources:

- Name : KINETRON
- Source: Linear Accelerator
- Energy: 4,5 MeV electrons
- Dose rate: from 4 Gy/min to  $4 \times 10^3$  Gy/s (mean dose rate)
- Applications:
  - Pulsed Radiolysis
  - Cells irradiations
  - Mice irradiations (total body, localized)



- Name: IBL 637
- Source: Cesium 137
- Energy: 662 keV photons
- Dose rate: 1 Gy/h to 10 Gy/min
- Applications:
  - Cells irradiations
  - Mice irradiations (total body)



- Name: Xrad320Dx
- Source: 320 kV X-rays generator
- Mean energy: from 30 keV to 160 keV
- Dose rate: from 0.05 Gy/min to 4 Gy/min
- Applications:
  - Cells irradiations
  - Mice irradiations (total body, localized)



Access to proton beams of Protontherapy Center of Orsay (as part of France Hadron)

- Source: Cyclotron (IBA)
- Energy: 76-201 MeV
- Raw or Spread Out Bragg Peak
- Dose rate: 0.1 to 20 Gy/min
- Applications:
  - Cells irradiations
  - Mice irradiations (total body, localized)



Coming Soon (available in 2014): irradiator/CT

- Source: 225 kV X-rays generator
- Mean Energy: 30-100 keV
- Dose rate: 0.05 to 1 Gy/min
- Applications:
  - Small fields irradiations (diameter: 1 mm)
  - Image guided radiotherapy



Frederic Pouzoulet



Sophie Heinrich



# La Physique Médicale demain: Perspectives en Radiothérapie Externe

## Conclusions

1) **Physique et technologie :**  
**vers la radiothérapie Adaptative**  
**avec optimisation du flux**

2) **Besoin d'ouverture en R&D :**  
**par ex vers la Biologie**

<b>Image</b>	<b>IGRT</b>
<b>Physics</b>	<b>PGRT</b>
<b>Biology</b>	<b>BGRT</b>
<b>Economical</b>	<b>ECRT</b>


.....

<b>Clinical</b>	<b>CGRT</b>
-----------------	-------------

<b>Social</b>	<b>SGRT</b>
---------------	-------------

# Proton and Carbon-Ion Therapy Facilities Around the World

Area resized according to the nation's population (2010)



*From Bill Chu, PTCOG 50, USA*

**Merci !**